Mechanism of Action:
- Synthetic analog of growth hormone-releasing factor
- Stimulates pulsatile secretion of endogenous GH
- Increases IGF-1 levels in blood plasma
- Selectively reduces visceral adipose tissue
Recommended for:
- Patients with HIV-associated lipodystrophy
- Individuals with abdominal obesity and metabolic syndrome
- Patients with insulin resistance
- Age-related increase in visceral fat volume
Research and Studies:
Multicenter clinical studies confirm:
- 15-18% reduction in visceral fat over 6 months of therapy
- 25-30% improvement in insulin sensitivity
- 20-25% reduction in triglyceride levels
- 2-3 kg increase in muscle mass with maintained diet
- FDA approval for HIV lipodystrophy treatment
Indications:
- HIV-associated lipodystrophy with excess abdominal fat
- Metabolic syndrome with visceral obesity
- Insulin resistance with abdominal obesity
- Age-related changes in fat distribution
The drug is dissolved in 1-2 ml of sterile water for injections and administered subcutaneously in the abdominal area once daily. Recommended dose is 2 mg per day. Treatment duration is determined individually, minimum course - 6 months.
Contraindications:
- Active malignant diseases
- Pregnancy and lactation
- Severe renal failure
- Acute cerebrovascular accidents
- Hypersensitivity to tesamorelin
Side Effects:
- Arthralgia and myalgia
- Peripheral edema
- Skin sensitivity disorders
- Increased blood glucose levels
- Injection site pain
